FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Disclosed is method of reducing immunogenicity of scFv antibody fragment, wherein method involves step for replacement of one or more amino acid residues of variable light chain domain in positions 101 and/or 148 (numbering AIE) and replacement of amino acid residues in positions 12, 103 and 144 (numbering AIE) variable domain of heavy chain.
EFFECT: disclosed is pharmaceutical composition with reduced immunogenicity, containing antibody fragment containing replacement of one or more amino acid residues of variable light chain domain in positions 101 and/or 148 (numbering AIE) and replacement of amino acid residues in positions 12, 103 and 144 (numbering AIE) variable domain of heavy chain.
11 cl, 5 dwg, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR PREDICTION, DETECTION AND REDUCTION OF NON-SPECIFIC INTERFERENCE OF PROTEINS IN METHODS OF ANALYSIS USING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULINS | 2012 |
|
RU2700630C2 |
| IL-8-BINDING ANTIBODIES AND USE THEREOF | 2016 |
|
RU2728430C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2016 |
|
RU2648152C2 |
| COMPOSITIONS FOR INHIBITION OF MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2636038C2 |
| ANTI-IDIOTYPICAL ANTIBODIES THAT INDUCE IMMUNE RESPONSE AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR | 1996 |
|
RU2172636C2 |
| IL-4 AND/OR IL-13 BINDING ANTIBODIES AND USING THEM | 2008 |
|
RU2580049C2 |
| VEGF INHIBITING STABLE AND SOLUBLE ANTIBODIES | 2009 |
|
RU2531523C9 |
| ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617966C2 |
| HUMANISED ANTIBODIES TO Toll-LIKE RECEPTORS 2 AND THEIR APPLICATIONS | 2010 |
|
RU2563344C2 |
| STRUCTURED ANTI-TGF-BETA ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | 2014 |
|
RU2681502C2 |
